Overall Score

Growth Runway

ABCL still has a long-term growth runway if its antibody discovery platform continues to convert into partnered programs and pipeline expansion.

The company’s very high gross margin profile (74.95% TTM) supports scalability if revenue growth accelerates.

Financial Strength

ABCL maintains a very strong liquidity position with a 12.77 current ratio and 2.26 cash ratio, giving it ample near-term flexibility.

Balance sheet leverage remains low, with debt-to-equity at 0.15 and net debt to EBITDA near zero.

Profitability Trend

Profitability remains deeply negative, with EBIT margin at -3.05 and net profit margin at -2.49 TTM.

Returns are still negative across the board, including ROE at -17.49% and ROIC at -14.95%, indicating the business is not yet generating economic profits.

Cash Flow Momentum

Free cash flow remains negative at -$179.5M TTM, and free cash flow yield is -5.16%, showing continued cash burn.

Operating cash flow is also negative, with OCF margin at -2.34% and OCF per share at -0.51.

Valuation Vs Growth

ABCL trades at a very rich sales multiple of 52.52x TTM, which leaves little room for execution missteps.

The valuation is partially offset by a strong cash position and low leverage, but the stock still requires substantial future growth to justify the multiple.